| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2013-08-27 |
| タイトル |
|
|
タイトル |
Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Osawa, Satoshi
Furuta, Takahisa
Sugimoto, Ken
Kosugi, Takashi
Terai, Tomohiro
Yamade, Mihoko
Takayanagi, Yasuhiro
Nishino, Masafumi
Hamaya, Yasushi
Kodaira, Chise
Yamada, Takanori
Iwaizumi, Moriya
Takagaki, Kosuke
Yoshida, Ken-ichi
Kanaoka, Shigeru
Ikuma, Mutsuhiro
|
| 書誌情報 |
en : BMC Cancer
巻 9,
p. 408,
発行日 2009-11-22
|
| 出版者 |
|
|
出版者 |
BioMed Central Ltd |
|
言語 |
en |
| 権利 |
|
|
権利情報 |
Copyright 2009 BioMed Central Ltd |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Protracted low-dose concurrent chemotherapy combined with radiation has been proposed for enhanced treatment results for esophageal cancer. We evaluated the efficacy and the toxicity of a novel regimen of daily low-dose nedaplatin (cis-diammine-glycolatoplatinum) and continuous infusion of 5-fluorouracil (5-FU) with radiation in patients with esophageal squamous cell carcinoma. Methods: Between January 2003 and June 2008, 33 patients with clinical stage I to IVB esophageal squamous cell carcinoma were enrolled. Nedaplatin (10 mg/body/day) was administered daily and 5-FU (500 mg/body/day) was administered continuously for 20 days. Fractionated radiotherapy for a total dose of 50.4-66 Gy was administered together with chemotherapy. Additional chemotherapy with nedaplatin and 5-FU was optionally performed for a maximum of 5 courses after chemoradiotherapy. The primary end-point of this study was to evaluate the tumor response, and the secondary end-points were to evaluate the toxicity and the overall survival. Results: Twenty-two patients (72.7%) completed the regimen of chemoradiotherapy. Twenty patients (60.6%) achieved a complete response, 10 patients (30.3%) a partial response. One patient (3.0%) had a stable disease, and 2 (6.1%) a progressive disease. The overall response rate was 90.9% (95% confidence interval: 75.7%-98.1%). For grade 3-4 toxicity, leukopenia was observed in 75.8% of the cases, thrombocytopenia in 24.2%, anemia in 9.1%, and esophagitis in 36.4%, while late grade 3-4 cardiac toxicity occurred in 6.1%. Additional chemotherapy was performed for 26 patients (78.8%) and the median number of courses was 3 (range, 1-5). The 1-, 2- and 3-year survival rates were 83.9%, 76.0% and 58.8%, respectively. The 1- and 2-year survival rates were 94.7% and 88.4% in patients with T1-3 M0 disease, and 66.2% and 55.2% in patients with T4/M1 disease. Conclusion: The treatment used in our study may yield a high complete response rate and better survival for each stage of esophageal squamous cell carcinoma. Trial registration: ClinicalTrials.gov Identifier: NCT00197444 |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
14712407 |
| 出版社DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1186/1471-2407-9-408 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
BMCCancer-2009_11-408.pdf (806.9 kB)
